Search
TP-271
go.drugbank.com/drugs/DB15040InvestigationalTP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271).
JSM 6427
go.drugbank.com/drugs/DB06139InvestigationalJSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed. … It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55.
Ranpirnase
go.drugbank.com/drugs/DB04950InvestigationalIt is being studied in the treatment of cancer. It is manufactured by Alfacell Corporation. It is the first ribonuclease to enter cancer clinical trials.
Econazole
go.drugbank.com/drugs/DB01127ApprovedA broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.
Mixtures: TRILON-E CREAMMethallenestril
go.drugbank.com/drugs/DB13143ExperimentalCategories: Sex Hormones and Modulators of the Genital SystemMethylestrenolone
go.drugbank.com/drugs/DB13533InvestigationalCategories: Sex Hormones and Modulators of the Genital SystemClemastine
go.drugbank.com/drugs/DB00283ApprovedInvestigationalAn ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
Opipramol
go.drugbank.com/drugs/DB12930InvestigationalOpipramol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeBecaplermin
go.drugbank.com/drugs/DB00102ApprovedInvestigationalBecaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae.
Reglitazar
go.drugbank.com/drugs/DB04971ExperimentalReglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.